MOFICEFT S 360MG TAB 10

About

Moficeft S 360mg, likely referring to Mycophenolate Sodium (MPS), is an enteric-coated formulation of mycophenolic acid, an immunosuppressive agent. It is primarily used to prevent organ rejection in patients who have undergone kidney transplantation. MPS works by selectively inhibiting inosine monophosphate dehydrogenase (IMPDH), an enzyme crucial for the de novo synthesis of guanosine nucleotides. This action specifically targets and suppresses the proliferation of T and B lymphocytes, which are essential for the immune response against transplanted organs. The enteric coating is designed to reduce gastrointestinal side effects by delaying the release of mycophenolic acid until it reaches the small intestine.

This formulation offers an alternative to mycophenolate mofetil (MMF) for patients who experience significant gastrointestinal intolerance with MMF. By providing targeted delivery, MPS aims to improve patient adherence and comfort while maintaining effective immunosuppression. It is typically used in combination with other immunosuppressants, such as calcineurin inhibitors and corticosteroids, to achieve optimal graft survival and minimize the risk of acute rejection episodes in transplant recipients.

Uses

• Prevention of organ rejection in kidney transplant recipients.
• Management of certain autoimmune diseases.
• Alternative for patients intolerant to Mycophenolate Mofetil due to GI side effects.
• Used in combination with other immunosuppressants.

Directions For Use

Take orally, typically twice daily, on an empty stomach. Do not crush or chew the tablets. Follow your doctor's prescribed dosage and schedule strictly.

Benefits

• Effective in preventing kidney transplant rejection.
• Reduced gastrointestinal side effects compared to Mycophenolate Mofetil.
• Improves patient adherence due to better tolerability.
• Helps improve long-term graft survival rates.
• Useful in managing certain autoimmune conditions.
• Allows for reduction in corticosteroid doses.

Side Effects

• Diarrhea
• Nausea
• Vomiting
• Abdominal pain
• Leukopenia (low white blood cell count)
• Anemia
• Thrombocytopenia (low platelet count)
• Increased risk of infections (bacterial, viral, fungal)
• Increased risk of lymphoma and other malignancies
• Hypertension
• Headache
• Tremor

Safety Measures

• Alcohol - No direct interaction, but general caution is advised due to potential for liver effects and overall health considerations in immunosuppressed patients.
• Pregnancy - Contraindicated due to a high risk of birth defects and miscarriage. Women of childbearing potential must use effective contraception.
• Breastfeeding - Contraindicated. Mycophenolate passes into breast milk and can cause serious adverse effects in the infant.
• Liver - Use with caution; dose adjustment may be needed in severe hepatic impairment due to altered drug metabolism.
• Kidney - Dose adjustment may be needed in severe renal impairment, as drug exposure can increase. Monitor renal function closely.
• Lung - Increased risk of opportunistic lung infections (e.g., CMV pneumonia) and interstitial lung disease. Monitor for respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.